Global Expansion Co-Diagnostics, Inc is actively engaging in international health events and exhibitions (Medical Korea 2026, Global Health Exhibition in Riyadh, Union World Conference on Lung Health) and pursuing partnerships with government and industry leaders, signaling readiness for channel partnerships, distributors, and regional deployments of their Co-Dx PCR Pro platform.

Home and Point-of-Care Potential The company cites readiness to launch a new Co-Dx PCR Pro instrument and tests aimed at at-home and point-of-care real-time PCR testing, presenting a sales opportunity to address remote or underserved markets with turnkey, affordable diagnostics solutions.

Leadership and Expertise Appointment of a new Chief Scientific Officer and ongoing engagement with thought leaders positions Co-Dx to bolster credibility with academic, clinical, and regulatory customers, enabling targeted outreach to healthcare systems, research labs, and potential adopters of the Co-Primers platform.

Platform Advantage With a patented Co-Primers technology and a scalable molecular diagnostics platform, there is a clear value proposition for strategic partnerships, OEM collaborations, and licensing deals to accelerate test development and expand catalog for infectious disease and life sciences assays.

Financial Gateways Recent financing activity and a mid-market revenue range indicate capacity for growth investments, enabling sales teams to approach mid-sized clinics, regional labs, and public-health programs with scalable purchasing options and potential for multi-year contracts on the Co-Dx solution stack.